Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Michel Farnier,Peter B. Jones,Randall Severance,Maurizio Averna,Elisabeth Steinhagen-Thiessen,Helen M. Colhoun,Yunling Du,Corinne Hanotin,Stephen Donahue +8 more
TLDR
The addition of alirocumab to rosuvastatin provided incremental LDL-C lowering versus adding ezetimibe or doubling the rosuVastatin dose, and patients with cardiovascular disease and low-density lipoprotein cholesterol achieved risk-based cholesterol targets.About:
This article is published in Atherosclerosis.The article was published on 2016-01-01 and is currently open access. It has received 165 citations till now. The article focuses on the topics: Rosuvastatin Calcium & Rosuvastatin.read more
Citations
More filters
Journal ArticleDOI
American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Paul S. Jellinger,Yehuda Handelsman,Paul D. Rosenblit,Zachary T. Bloomgarden,Vivian Fonseca,Alan J. Garber,George Grunberger,Chris K. Guerin,David S.H. Bell,Jeffrey I. Mechanick,Rachel Pessah-Pollack,Kathleen Wyne,Donald A. Smith,Eliot A. Brinton,Sergio Fazio,Michael H. Davidson,Farhad Zangeneh,Michael A. Bush +17 more
TL;DR: This CPG is a practical tool that endocrinologists, other health care professionals, health-related organizations, and regulatory bodies can use to reduce the risks and consequences of dyslipidemia.
Journal ArticleDOI
Європейське керівництво з профілактики серцево-судинних захворювань у клінічній практиці — 2016
Journal ArticleDOI
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi,Andrew E. Moran,Pamela G. Coxson,Joanne Penko,Daniel A. Ollendorf,Steven D. Pearson,Jeffrey A. Tice,David Sanchez-Migallon Guzman,Kirsten Bibbins-Domingo +8 more
TL;DR: Using PCSK9 inhibitor use in patients with heterozygous FH or ASCVD did not meet generally acceptable incremental cost-effectiveness thresholds and was estimated to increase US health care costs substantially, compared with initiating statins in all statin-tolerant individuals who are not currently using statins.
Journal ArticleDOI
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Henry N. Ginsberg,Daniel J. Rader,Frederick J. Raal,John R. Guyton,Marie T. Baccara-Dinet,Christelle Lorenzato,Robert Pordy,Erik S.G. Stroes +7 more
TL;DR: In patients with heFH and very high LDL-C baseline levels despite maximally tolerated statin ± other LLT, alirocumab 150 mg Q2W demonstrated significant reductions in cholesterol levels with 41 % of patients achieving predefined cholesterol goals.
Journal ArticleDOI
PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
Amand F. Schmidt,Lucy S Pearce,John T. Wilkins,John P. Overington,Aroon D. Hingorani,Juan P. Casas +5 more
TL;DR: A large number of trials randomised participants to alirocumab, three trials to bococizumab, one to RG7652, and four to evolocumab found that PCSK9 inhibitors appeared to have a stronger protective effect on CVD risk, although with considerable uncertainty.
References
More filters
Journal ArticleDOI
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Massimo Piepoli,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,FD Richard Hobbs,Maja Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Y.M. Smulders,Monica Tiberi,H. Bart van der Worp,Ineke van Dis,W M Monique Verschuren +25 more
TL;DR: In this paper, a randomized clinical trial was conducted to evaluate the effect of preterax and Diamicron Modified Release Controlled Evaluation (MDE) on the risk of stroke.
Journal ArticleDOI
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone,Jennifer G. Robinson,Alice H. Lichtenstein,C. Noel Bairey Merz,Conrad B. Blum,Robert H. Eckel,Anne C. Goldberg,David Lee Gordon,Daniel Levy,Donald M. Lloyd-Jones,Patrick E. McBride,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Karol E. Watson,Peter W.F. Wilson +15 more
TL;DR: Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2 The goals of the …
Journal ArticleDOI
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Colin Baigent,L Blackwell,Jonathan Emberson,Lisa Holland,Christina Reith,Neeraj Bhala,Richard Peto,Elizabeth H Barnes,Anthony C Keech,John Simes,Rory Collins +10 more
TL;DR: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth.
Journal ArticleDOI
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Joep Perk,G. De Backer,Helmut Gohlke,Ian D. Graham,Zeljko Reiner,Monique Verschuren,Christian Albus,Pascale Benlian,G Boysen,Renata Cifkova,Christi Deaton,Shah Ebrahim,Miles Fisher,Giuseppe Germanò,Richard J. Hobbs,Arno W. Hoes,Sehnaz Karadeniz,Alessandro Mezzani,Eva Prescott,Lars Rydén,Martin Scherer,M Syvänne,Scholte op Reimer Wjm.,Christiaan Vrints,David R. Wood,José Luis Zamorano,Faiez Zannad +26 more
TL;DR: The ESC Guidelines and Expert Consensus Documents as mentioned in this paper summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic means.
Journal ArticleDOI
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆
Alberico L. Catapano,Zeljko Reiner,Guy De Backer,Ian D. Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul N. Durrington,Serap Erdine,Julian Halcox,Richard J. Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David R. Wood +17 more
TL;DR: These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat.